Century Therapeutics, Inc. (NASDAQ:IPSC) Stock Has Consensus Price Target of $4.75

Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) have earned a consensus recommendation of “Hold” from the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have given a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $4.75.

IPSC has been the subject of several research reports. Wall Street Zen raised shares of Century Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Century Therapeutics in a research report on Tuesday, September 29th.

Century Therapeutics Price Performance

Century Therapeutics stock opened at $1.37 on Tuesday. The company has a market cap of $248.07 million, a PE ratio of -1.47 and a beta of 1.67. The company has a fifty day moving average price of $1.84 and a two-hundred day moving average price of $2.10. Century Therapeutics has a 12 month low of $0.43 and a 12 month high of $3.04.

Century Therapeutics (NASDAQ:IPSC) last released its earnings results on Wednesday, August 12th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.06). Equities research analysts anticipate that Century Therapeutics will post -0.51 earnings per share for the current year.

Hedge Funds Weigh In On Century Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Versant Venture Management LLC bought a new position in shares of Century Therapeutics during the first quarter valued at approximately $27,495,000. BlackRock Inc. bought a new stake in shares of Century Therapeutics in the 2nd quarter worth approximately $19,825,000. Commodore Capital LP bought a new stake in shares of Century Therapeutics in the 1st quarter worth approximately $19,652,000. Seven Fleet Capital Management LP acquired a new position in Century Therapeutics during the 2nd quarter valued at approximately $10,652,174. Finally, Trails Edge Capital Partners LP acquired a new position in Century Therapeutics during the 2nd quarter valued at approximately $10,130,674. 50.20% of the stock is currently owned by institutional investors and hedge funds.

About Century Therapeutics

Century Therapeutics, Inc (NASDAQ:IPSC) is a biotechnology company developing allogeneic cell therapies for cancer. The company uses induced pluripotent stem cell (iPSC) technology to create potentially scalable immune-cell products designed to treat patients without relying on cells collected from each individual patient.

Century’s research focuses primarily on iPSC-derived natural killer (NK) cells and T cells that are genetically engineered to recognize and attack cancer cells. Its pipeline has included investigational chimeric antigen receptor (CAR) cell therapies targeting blood cancers, including B-cell malignancies, with the goal of providing readily available, “off-the-shelf” treatments.

Founded in 2018 and headquartered in Philadelphia, Pennsylvania, Century Therapeutics conducts research and development activities in the United States.